Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetaphil Restoraderm is a specialized line of over-the-counter therapeutic skincare products developed by Galderma for the management of eczema-prone and atopic skin. The formulation utilizes a combination of ceramide technology and filaggrin breakdown products, such as arginine and sodium pyrrolidone carboxylic acid (PCA), to replenish the skin's natural moisturizing factor (NMF) and restore the epidermal barrier. By strengthening the skin barrier, the product helps to reduce transepidermal water loss and protect against external irritants and allergens that trigger flares. Clinical evidence supports its use in reducing the incidence of atopic dermatitis in high-risk infants and improving symptoms such as pruritus and skin dryness in adults and children with mild-to-moderate eczema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetaphil Restoraderm.